Figure 3. HR for outcomes of interest respect by HCC. Mortality: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, age (donor), BMI (donor), cardio-cerebrovascular diseases, anaemia. Rejection/graft loss: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, diabetes, thyroid disorders. Infections: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, anaemia/antianemics, BMI (donor), anticoagulants/antiplatelet. Diabetes: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, diuretics. Cancer: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, diuretics, LMAs. MACE: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, Charlson index. Use of LMAs: adjusted for region, sex, age, discharge year, renal disease and dialysis, score MELD, cardio-cerebrovascular diseases. Note: TAC: Tacrolimus; BMI: body mass index; IR: incidence rate; LMAs: lipid-modifying agents; MACE: major adverse cardiovascular events; MELD: model for end-stage liver disease; mTORi:molecular target of rapamycin inhibitors.